Research Article
Molecular Characterization of the Tumor Suppressor Candidate 5 Gene: Regulation by PPAR and Identification of TUSC5 Coding Variants in Lean and Obese Humans
Table 1
Relative transcript abundances of PPAR target genes in HepG2 cells experimentally-expressing different PPAR isoforms, in the presence or absence of isoform-selective agonists.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ‡Using HepG2 Tet-off human PPAR isoform-specific overexpressing stable cell lines [14] (see Methods); /treatment. †PPAR isoform-selective agonists used for PPAR, , 1, 2 experiments were, respectively, GW7647 (1 M), GW501516 (100 nM), and rosiglitazone (1 M); cells were treated for 24 hours prior to mRNA collection. n.d.: not detectable (note that Tusc5, adiponectin, and leptin transcripts were readily detected in a human WAT sample run in parallel). | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||